Evidence map›Paper›PMID 38361356›Full record

ArticleAnti-inflammatory & anti-allergy agents in medicinal chemistry2024

Cinnamic Acid Ameliorates Acetic Acid-induced Inflammatory Response through Inhibition of TLR-4 in Colitis Rat Model.

Zahra Rezaei, Saeideh Momtaz, Pardis Gharazi, Mahban Rahimifard, Maryam Baeeri, Ali Reza Abdollahi, Mohammad Abdollahi, Amirhossein Niknejad, Danial Khayatan, Mohammad Hosein Farzaei and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Cinnamon and Derivatives as Modulators of Toll-like Receptors.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Zahra RezaeiDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Saeideh MomtazMedicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
Pardis GharaziDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mahban RahimifardDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, And Toxicology & Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
Maryam BaeeriDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, And Toxicology & Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
Ali Reza AbdollahiDepartment of Pathology, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad AbdollahiDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, And Toxicology & Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
Amirhossein NiknejadDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Danial KhayatanDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mohammad Hosein FarzaeiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Amir Hossein AbdolghaffariDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Islamic Azad University Medical Branch of Tehran · IRTehran University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRKermanshah University of Medical Sciences · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCinnamic acid, an active compound in cinnamon spp., has anti-inflammatory and antioxidant characteristics and is favorable in managing inflammatory bowel diseases.

objectivesEvaluate cinnamic acid's effects on colitis in rats.

methodsTo induce colitis in experimental rats, excluding the sham group, a 4% intrarectal solution of acetic acid was administered. The rats were then given oral doses of cinnamic acid at 30, 45, and 90 mg/kg for two days. The animals were assessed for macroscopic and microscopic changes, and the levels of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) were measured using Eliza kits. Additionally, real-time PCR was performed to examine the gene level of toll-like receptor 4 (TLR-4) in the colon.

resultsEffective reduction of inflammation in acetic acid-induced colitis was achieved through Cinnamic acid administration at doses of 45 and 90 mg/kg. The decrease was achieved by inhibiting the activities of TNF-α, IL-6, and MPO while downregulating the expression of TLR-4. It is important to note that macroscopic and microscopic evaluations were significant in determining the effectiveness of cinnamic acid in reducing inflammation.

conclusionDownregulation of inflammatory cytokines and TLR-4 expression may contribute to cinnamic acid's anti-inflammatory effect.

Indexed as

Acetic AcidAnti-Inflammatory AgentsCinnamatesColitisDisease Models, AnimalPeroxidaseToll-Like Receptor 4AnimalsColonInterleukin-6MaleRatsRats, WistarTumor Necrosis Factor-alphaAcetic AcidAnti-Inflammatory AgentsCinnamatescinnamic acidInterleukin-6PeroxidaseTlr4 protein, ratToll-Like Receptor 4Tumor Necrosis Factor-alphaCinnamic acidInflammatory bowel disease (IBD)Interleukin-6 (IL-6)Myeloperoxidase (MPO)Toll-like receptor- 4 (TLR-4)Tumor necrosis factor-alpha (TNF-α).

Identifiers

PMID38361356
OpenAlexW4391439817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.